Riabni

E261832

Riabni is a biosimilar monoclonal antibody to rituximab used in the treatment of certain cancers and autoimmune diseases.

All labels observed (1)

Label Occurrences
Riabni canonical 1

How this entity was disambiguated

Statements (44)

Predicate Object
instanceOf biopharmaceutical drug
biosimilar medicine
monoclonal antibody
rituximab biosimilar
affectsCellType B lymphocytes
hasActiveIngredient rituximab-arrx
hasATCClass L01XC02 (rituximab class)
hasBlackBoxWarning fatal infusion reactions
hepatitis B virus reactivation
progressive multifocal leukoencephalopathy
severe mucocutaneous reactions
hasCommonAdverseEffect chills
fever
infections
infusion-related reactions
neutropenia
hasDosageForm solution for intravenous infusion
hasDrugClass CD20-directed cytolytic antibody
hasGenericName rituximab-arrx
hasIndication chronic lymphocytic leukemia
diffuse large B-cell lymphoma
follicular lymphoma
Wegener's granulomatosis
surface form: granulomatosis with polyangiitis

microscopic polyangiitis
non-Hodgkin lymphoma
rheumatoid arthritis
hasMechanismOfAction binds to CD20 on B lymphocytes
induces B-cell lysis
mediates antibody-dependent cellular cytotoxicity
mediates complement-dependent cytotoxicity
hasMolecularType chimeric monoclonal antibody
hasRouteOfAdministration intravenous infusion
hasSpeciesOrigin human-mouse chimeric
hasTarget CD20 protein
surface form: CD20 antigen
hasTherapeuticArea immunology
oncology
rheumatology
isAdministeredBy healthcare professional
isApprovedBy Food and Drug Administration
surface form: U.S. Food and Drug Administration
isBiosimilarTo Rituxan
Rituxan
surface form: rituximab
isContraindicatedIn patients with severe active infections
isUsedFor treatment of certain autoimmune diseases
treatment of certain cancers

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Rituxan hasBiosimilar Riabni